About Sonnest, Inc.
Sonnest, Inc. is pre-clinical healthcare company developing Electrast™, an ultrasound imaging drug that circulates through the body in the inactive state (dark on ultrasound) and is selectively activated (turned on) in the myocardium. With Electrast™ doctors will be able to evaluate perfusion of the heart quickly and cost-effectively at the point of care without exposure to ionizing radiation or toxic dies. The technology was developed by a talented team of cardiologists and chemical engineers at Drexel University with grant funding from the Coulter-Drexel Program and the inventors partnered with a team of successful serial healthcare entrepreneurs who have worked together for over 15 years across multiple companies to form Sonnest.
|
|
|
1-10 employees
View all Sonnest, Inc. employees
|
|
Medical Devices
|
|
323 West Camden Street, Suite 600, Baltimore, Md 21201, US
|
|
None
|
Sonnest, Inc. Alternatives
Frequently Asked Questions about Sonnest, Inc.
The decision makers in Sonnest, Inc. are Andrew Kohut, Peter Boyd, Josh White, etc. Click to Find Sonnest, Inc. decision makers emails.
Sonnest, Inc. Staff Directory
Search Sonnest, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
